Clinical trials: Glucose Response
PreDiabetes, Dysbiosis
Assessing Gut Microbiota Mediated Health Outcomes of Whole Wheat and Its Major Bioactive Components
This study will investigate the gut microbiota-mediated effects of whole wheat consumption on human health in adults with pre-diabetes.
- Conditions
- PreDiabetes, Dysbiosis, Endotoxemia, Inflammation
- Trial name
- NCT05318183
- Testing
- Whole Wheat Bread, White Bread (control)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Ohio State University
Diabetes Mellitus, Type 2
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin.
- Trial name
- NCT05486065
- Testing
- Semaglutide
- Where
- 130 sites in United States, Greece and 3 more
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Diabetes
GLP1R Polymorphisms and Response to GLP1
Glucagon-like Peptide-1 (GLP-1) is an important incretin hormone which acts as a powerful insulin secretagogue. Defects in GLP-1 synthesis and secretion are thought to be part of the pathogenesis of type 2 diabetes.
- Trial name
- NCT00588380
- Testing
- GLP-1
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Postprandial Hyperglycemia
Comparison of the Postprandial Glycemic and Insulinemic Response After a Fibersym Containing Cookie With a Control
Fibersym® is a RS4-type resistant modified wheat starch in which over 85% of the total starch is resistant starch as measured by AOAC method 991.43.
- Trial name
- NCT04820322
- Testing
- Fibersym, Control cookie
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MGP Ingredients, Inc.
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
DEFEND-2 is a Phase 3 confirmatory study for the Phase 3 DEFEND-1 study. The study objective is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo.
- Trial name
- DEFEND-2 (NCT01123083)
- Testing
- Otelixizumab
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population.
- Trial name
- ASPIRE (NCT01497938)
- Testing
- Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
This is a stepped glucose clamp study designed to investigate the effect of treatment with albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus.
- Trial name
- NCT01475734
- Testing
- albiglutide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Type2 Diabetes, Cardiovascular Diseases
Peanuts and Glycemic Control
A two-period randomized crossover study will be conducted to determine the effect of peanuts on glycemic control, and elucidate the role of the microbiome in glucose regulation, in individuals with impaired fasting glucose.
- Trial name
- NCT03654651
- Testing
- Peanut, High carbohydrate snack
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Penn State University